Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2022 08:00 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Submission of IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab

SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
July 27, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
July 26, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
June 02, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
May 16, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
May 11, 2022 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
May 04, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022

SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
April 19, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.

SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
March 23, 2022 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
March 15, 2022 16:02 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update

Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022 SAN...